-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune Checkpoint Inhibitors (ICI) and their introduction into a variety of tumor indication treatment models can be said to be the biggest transformative force in cancer treatment in the past decade.
According to an article recently published by the leading data and analysis company GlobalData, this generation of local Chinese ICI brands are currently preparing to obtain approval for multiple tumor indications in the Chinese and international markets.
Source: bcgsc.
Dr.
Local Chinese products were promoted in China by entering the National Reimbursement Drug List (NRDL), and then significantly discounted compared with international brands, creating a significant commercial advantage.
International ICI brands are seeking market access in China, and now they need to strike a balance between declining drug prices and the opportunity to target a large patient population, or find treatment areas that are underserved and no local products have been approved.
Key statistics of phase 3 clinical trials of domestic ICI products in China (Source: GlobalData)
At present, the domestic ICIs in China are from Junshi Bio-Toripalimab® (toripalimab), Cinda Bio-Daboshu® (sintilimab, Sintilimab), BeiGene Baizean® ( tislelizumab, tislelizumab), Hengrui Medicine Erika® (camrelizumab, carrelizumab) are the leaders, with the most extensive clinical development projects spanning multiple tumor indications.
Due to the fierce competitive environment, Chinese doctors’ familiarity with international brands, and severe pricing pressure, the commercial potential of local ICI may be limited, but international market access may provide an additional source of income.
Dr.
In the field of ICI, the latest examples include Junshi Biosciences and AstraZeneca/Coherus Biosciences (Tuoyi®), Cinda Biosciences and Eli Lilly (Daboshu®), BeiGene and Novartis (Baizean®) Agreement.
Dr.
